Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 9,649 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Human Clear all
Terminated Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19)

NCT04547140
View directory record Official record
Conditions
COVID-19
Interventions
Liquid Alpha1-Proteinase Inhibitor (Human), Placebo, Standard Medical Treatment
Biological · Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 24, 2026, 2:09 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Cannabis Use, Cognition, and the Endocannabinoid System in HIV

NCT04883255
View directory record Official record
Conditions
HIV-1-infection
Interventions
10 mg Δ9-tetrahydrocannabinol (THC), 600 mg cannabidiol (CBD), Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 65 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 24, 2026, 2:09 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Fasting on Newly Diagnosed Breast Cancer

NCT02379585
View directory record Official record
Conditions
HER2-positive Breast Cancer
Interventions
Doxorubicin, cyclophosphamide, paclitaxel, docetaxel, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 24, 2026, 2:09 AM EDT
Completed No phase listed Observational

Measuring Alterations of DNA in Human Blood

NCT00178308
View directory record Official record
Conditions
Neoplasms
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
21 Years to 70 Years
Enrollment
24 participants
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2006 · Synced Oct 24, 2026, 2:09 AM EDT
Terminated Phase 1 Interventional

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

NCT06343376
View directory record Official record
Conditions
Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, EGFRt/19-28z/IL-12 CAR T-lymphocytes, Fludarabine Phosphate, Leukapheresis, Multigated Acquisition Scan, Positron Emission Tomography
Procedure · Drug · Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 24, 2026, 2:09 AM EDT
Recruiting Phase 3 Interventional

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

NCT06545955
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Interventions
Nadofaragene Firadenovec, Gemcitabine, Docetaxel, Pembrolizumab
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
40
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 24, 2026, 2:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-323 in Healthy Subjects

NCT05587478
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-323, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2023 · Synced Oct 24, 2026, 2:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Metabolic Health in Patients With Diastolic Dysfunction

NCT03448185
View directory record Official record
Conditions
Obesity, Heart Failure, Diastolic, Metabolic Syndrome
Interventions
High intensity exercise, Omega-3 fish oil, Yoga, olive oil capsules
Behavioral · Dietary Supplement
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
40 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 24, 2026, 2:09 AM EDT
Terminated Phase 2 Interventional Results available

Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous Melanoma

NCT05200143
View directory record Official record
Conditions
Refractory Cutaneous Melanoma
Interventions
Ipilimumab, Nivolumab, Cabozantinib
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 24, 2026, 2:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Normal Lacritin Levels in Human Tears- Development of a New Clinical Assay

NCT00487643
View directory record Official record
Conditions
Tear Protein Lacritin in Human Tears
Interventions
Tear Collection
Procedure
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
21 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 11, 2014 · Synced Oct 24, 2026, 2:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of Levoketoconazole and Metformin

NCT03880825
View directory record Official record
Conditions
Healthy Subjects
Interventions
Metformin 500 mg Oral Tablet, Levoketoconazole 150 - 600 mg (BID)
Drug
Lead sponsor
Cortendo AB
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Oct 24, 2026, 2:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Interactions of Human Gut Microbiota With Intestinal Sweet Taste Receptors

NCT03032640
View directory record Official record
Conditions
Obesity
Interventions
Oral Glucose Tolerance Test (OGTT), Assessment of dietary compliance, Stool sampling, Sodium Saccharin, Placebo, Lactisole
Other
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 24, 2026, 2:09 AM EDT
Completed Phase 2 Interventional Results available

A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI

NCT02182440
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
recAP, Placebo
Biological · Other
Lead sponsor
AM-Pharma
Industry
Eligibility
18 Years to 85 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Birmingham, Alabama • Tampa, Florida • Idaho Falls, Idaho + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 24, 2026, 2:09 AM EDT
Recruiting Not applicable Interventional

Improving Cochlear Implant Outcomes Through Modeling and Programming Strategies Based on Human Inner Ear Pathology

NCT07683689
View directory record Official record
Conditions
Deafness
Interventions
Everyday Clinical Listening Program (Control), ENI-Based Experimental Program 1, ENI-Based Experimental Program 2
Device
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 24, 2026, 2:09 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

NCT01727089
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma
Interventions
Anti-Endoglin Chimeric Monoclonal Antibody TRC105, Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
28
States / cities
Duarte, California • Los Angeles, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 24, 2026, 2:09 AM EDT
Completed Not applicable Interventional

Human Breastmilk in Children Receiving a Bone Marrow Transplant

NCT02025478
View directory record Official record
Conditions
Bone Marrow Transplant- Autologous or Allogeneic
Interventions
Breastmilk
Dietary Supplement
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Up to 5 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 24, 2026, 2:09 AM EDT
Terminated Phase 1 Interventional

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma

NCT01106235
View directory record Official record
Conditions
Stage IV Melanoma
Interventions
therapeutic autologous lymphocytes, aldesleukin, cyclophosphamide, biopsy
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 21, 2011 · Synced Oct 24, 2026, 2:09 AM EDT
Completed No phase listed Observational

Ultrasonic Perfusion Estimation in Calf Muscle

NCT04755335
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Ultrasound
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 24, 2026, 2:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051

NCT03301090
View directory record Official record
Conditions
Corona Virus Infection
Interventions
Placebo, REGN3048, REGN3051
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 24, 2026, 2:09 AM EDT
Completed Phase 2 Interventional Results available

Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy

NCT01679197
View directory record Official record
Conditions
Fatty Liver Disease, Nonalcoholic, Nonalcoholic Steatohepatitis, Lipodystrophy
Interventions
Metreleptin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
5 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 24, 2026, 2:09 AM EDT
Not listed No phase listed Observational

Evolutionary and Sociocultural Aspects of Human Milk Composition

NCT02670278
View directory record Official record
Conditions
Breast Milk Collection
Interventions
Not listed
Lead sponsor
Washington State University
Other
Eligibility
1 Month and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Pullman, Washington
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 24, 2026, 2:09 AM EDT
Completed Phase 1 Interventional

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

NCT01769755
View directory record Official record
Conditions
Crohns Disease
Interventions
PDA001, Vehicle Controlled Placebo
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 24, 2026, 2:09 AM EDT
Completed Phase 1 Interventional

First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies

NCT01971515
View directory record Official record
Conditions
Solid Tumor
Interventions
MSC2363318A, MSC2363318A plus Trastuzumab, MSC2363318A plus Tamoxifen
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 24, 2026, 2:09 AM EDT
Terminated Not applicable Interventional

Effects of TUDCA on Endothelial Function in Type 2 DM

NCT03462940
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Insulin Response, Endothelial Dysfunction
Interventions
Tauroursodeoxycholic acid
Dietary Supplement
Lead sponsor
Boston University
Other
Eligibility
21 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 24, 2026, 2:09 AM EDT